Thursday, April 9, 2020

Thursday, April 9, 2020

SOLITON, INC.: Soliton's FDA Cleared RAP Device is Granted Two Additional Key Patents

Soliton, Inc. issued the following announcement on Oct. 15.

Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical technology company that has developed a new acoustic shockwave device, today announced that the Taiwan Intellectual Property Office had issued our patent entitled, "Taiwan Divisional Patent Application No. 107115437 from TW101125235; Entitled 'APPARATUS AND METHOD FOR GENERATING THERAPEUTIC SHOCKWAVES AND LASER LIGHT'" by Dr. Christopher C. Capelli et al. Additionally, the Japanese Patent Office issued our patent entitiled, "Japanese Divisional Patent Application No. 2018-008760 from JP 2015-561713 and PCT/US2014/021746; In the name of Soliton, Inc. and the Board of Regents of the University of Texas System; 'RAPID PULSE ELECTROHYDRAULIC SHOCKWAVE GENERATOR'" by Dr. Christopher C. Capelli et al.

Dr. Chris Capelli, CEO of Soliton, said, "We now have 8 patent families and over 60 issued or pending patents for our Rapid Acoustic Pulse, or 'RAP' device. Extending our broad patent portfolio to key international markets has been an important part of our IP strategy. We are pleased to see the patent offices in Japan and Taiwan validate our intellectual property through the issuance of these patents."


Join our more than 200K fans here to follow the Company:


About Soliton, Inc.

Soliton, Inc. is a medical device company with a novel and proprietary platform technology licensed from MD Anderson. The Company's first FDA cleared commercial product will use rapid pulses of acoustic shockwaves as an accessory to lasers for the removal of unwanted tattoos. The Company is based in Houston, Texas, and is actively engaged in bringing the Rapid Acoustic Pulse ("RAP") device to the market. The Company believes this "Soliton" method has the potential to lower tattoo removal costs for patients, while increasing profitability to practitioners, compared to current laser removal methods. Soliton is investigating potential additional capabilities of the RAP technology in preclinical testing, including the potential to assist existing fat reduction technology in the reduction of fat as well as improving the appearance of cellulite by creating mechanical stress at the cellular level and inducing significant collagen growth.

For more information about the Company, please visit:

Original source can be found here.

Organizations in this Story

Soliton, Inc.

More News

FDA Reporter